Table 9.

Other TKIs, target and main clinical indications or trials.

Name (Code) Trade Name	Targets	Approved Clinical Indications or Clinical Trial Study
Bosutinib (SKI-606)	SRC, STAT3	Under development in breast cancer (NCT03854903) and other solid tumors (NCT03023319)
Pexmetinib (ARRY-614)	MAPK, Tie-2	Under development in solid tumors (NCT04074967)
Dubermatinib (TP-0903)	Axl	Under development in solid tumors (NCT02729298)
Bemcentinib (BGB324)	Axl	Under development in breast cancer (NCT03184558), pancreatic cancer (NCT03649321), and SNCLC (NCT03184571)
Sitravatinib (MGCD516)	Axl, VEGFR3	Under development in several solid tumors
Ningetinib (C31H29FN4O5)	Axl, c-MET, VEGFR2	Under development in NSCLC (NCT03758287)